Omacetaxine Mepesuccinate: A New Treatment Option for Patients With Chronic Myelogenous Leukemia
Sandra E. Kurtin, RN, MS, AOCN®, ANP-C, and Lisa Matta, RN, MSN
From University of Arizona Cancer Center, Tucson, Arizona
Ms. Kurtin has acted as a consultant for Teva; Ms. Matta has acted as an advisor for Teva.
Correspondence to: Sandra E. Kurtin, RN, MS, AOCN®, ANP-C, University of Arizona Cancer Center, 6950 North Chaparral Place, Tucson, AZ 85718. E-mail: firstname.lastname@example.org
From University of Arizona Cancer Center, Tucson, Arizona |
DOI: 10.6004/jadpro.2013.4.4.6 |
© 2013 Harborside Press®
Recently, the FDA approved omacetaxine mepesuccinate (Synribo) for use in adult patients with chronic- or accelerated-phase chronic myelogenous leukemia with resistance and/or intolerance to two or more tyrosine kinase inhibitors. Learn about the mechanism of action, key trials, management strategies, and response evaluation for patients receiving omacetaxine.
For access to the full length article, please sign in